These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1033 related articles for article (PubMed ID: 9288176)

  • 41. Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide delta opioid receptor agonist.
    Calderon SN; Rothman RB; Porreca F; Flippen-Anderson JL; McNutt RW; Xu H; Smith LE; Bilsky EJ; Davis P; Rice KC
    J Med Chem; 1994 Jul; 37(14):2125-8. PubMed ID: 8035418
    [No Abstract]   [Full Text] [Related]  

  • 42. Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities.
    Lattanzi R; Spetea M; Schüllner F; Rief SB; Krassnig R; Negri L; Schmidhammer H
    J Med Chem; 2005 May; 48(9):3372-8. PubMed ID: 15857143
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Unique high-affinity synthetic mu-opioid receptor agonists with central- and systemic-mediated analgesia.
    Okada Y; Tsuda Y; Fujita Y; Yokoi T; Sasaki Y; Ambo A; Konishi R; Nagata M; Salvadori S; Jinsmaa Y; Bryant SD; Lazarus LH
    J Med Chem; 2003 Jul; 46(15):3201-9. PubMed ID: 12852751
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D-2-Nal(4)]endomorphin-2 (Antanal-2).
    Fichna J; do-Rego JC; Chung NN; Lemieux C; Schiller PW; Poels J; Broeck JV; Costentin J; Janecka A
    J Med Chem; 2007 Feb; 50(3):512-20. PubMed ID: 17266203
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2.
    Vig BS; Zheng MQ; Murray TF; Aldrich JV
    J Med Chem; 2003 Sep; 46(19):4002-8. PubMed ID: 12954053
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selective opioid dipeptides.
    Temussi PA; Salvadori S; Amodeo P; Bianchi C; Guerrini R; Tomatis R; Lazarus LH; Picone D; Tancredi T
    Biochem Biophys Res Commun; 1994 Feb; 198(3):933-9. PubMed ID: 8117299
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BU48: a novel buprenorphine analog that exhibits delta-opioid-mediated convulsions but not delta-opioid-mediated antinociception in mice.
    Broom DC; Guo L; Coop A; Husbands SM; Lewis JW; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2000 Sep; 294(3):1195-200. PubMed ID: 10945877
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy.
    McLamore S; Ullrich T; Rothman RB; Xu H; Dersch C; Coop A; Davis P; Porreca F; Jacobson AE; Rice KC
    J Med Chem; 2001 Apr; 44(9):1471-4. PubMed ID: 11311071
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preclinical pharmacology of AZD2327: a highly selective agonist of the δ-opioid receptor.
    Hudzik TJ; Maciag C; Smith MA; Caccese R; Pietras MR; Bui KH; Coupal M; Adam L; Payza K; Griffin A; Smagin G; Song D; Swedberg MD; Brown W
    J Pharmacol Exp Ther; 2011 Jul; 338(1):195-204. PubMed ID: 21444630
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.
    Greiner E; Spetea M; Krassnig R; Schüllner F; Aceto M; Harris LS; Traynor JR; Woods JH; Coop A; Schmidhammer H
    J Med Chem; 2003 Apr; 46(9):1758-63. PubMed ID: 12699394
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro potency, affinity and agonist efficacy of highly selective delta opioid receptor ligands.
    Kramer TH; Davis P; Hruby VJ; Burks TF; Porreca F
    J Pharmacol Exp Ther; 1993 Aug; 266(2):577-84. PubMed ID: 8394911
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
    Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
    Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors.
    Thompson CM; Wojno H; Greiner E; May EL; Rice KC; Selley DE
    J Pharmacol Exp Ther; 2004 Feb; 308(2):547-54. PubMed ID: 14600248
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prazosin-related compounds. Effect of transforming the piperazinylquinazoline moiety into an aminomethyltetrahydroacridine system on the affinity for alpha1-adrenoreceptors.
    Rosini M; Antonello A; Cavalli A; Bolognesi ML; Minarini A; Marucci G; Poggesi E; Leonardi A; Melchiorre C
    J Med Chem; 2003 Nov; 46(23):4895-903. PubMed ID: 14584940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.
    Le Bourdonnec B; Goodman AJ; Graczyk TM; Belanger S; Seida PR; DeHaven RN; Dolle RE
    J Med Chem; 2006 Dec; 49(25):7290-306. PubMed ID: 17149859
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of aromatic amino acid substitutions in the 3-position of cyclic beta-casomorphin analogues on mu-opioid agonist/delta-opioid antagonist properties.
    Schmidt R; Wilkes BC; Chung NN; Lemieux C; Schiller PW
    Int J Pept Protein Res; 1996 Nov; 48(5):411-9. PubMed ID: 8956074
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dihydromorphine-peptide hybrids have mu receptor antagonistic and delta receptor agonistic activity on the mouse vas deferens and bind with high affinity to opioid receptors in rat brain.
    Smith CB; Medzihradsky F; Woods JH
    NIDA Res Monogr; 1986; 75():189-92. PubMed ID: 2828970
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist.
    Bennett MA; Murray TF; Aldrich JV
    J Pept Res; 2005 Mar; 65(3):322-32. PubMed ID: 15787962
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis and opioid activity of side-chain-to-side-chain cyclic dynorphin A-(1-11) amide analogues cyclized between positions 2 and 5. 1. Substitutions in position 3.
    Vig BS; Murray TF; Aldrich JV
    J Med Chem; 2004 Jan; 47(2):446-55. PubMed ID: 14711314
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 7-Arylidenenaltrexones as selective delta1 opioid receptor antagonists.
    Ohkawa S; Portoghese PS
    J Med Chem; 1998 Oct; 41(21):4177-80. PubMed ID: 9767654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.